Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial

https://doi.org/10.1016/j.jdiacomp.2015.10.018Get rights and content

Abstract

Aims

We aimed to analyze the impact of baseline factors on the efficacy of α-lipoic acid (ALA) over 4 years in the NATHAN 1 trial.

Methods

This was a post-hoc analysis of the NATHAN 1 trial, a 4-year randomized study including 460 diabetic patients with mild-to-moderate polyneuropathy using ALA 600 mg qd or placebo. Amongst others, efficacy measures were the Neuropathy Impairment Score of the lower limbs (NIS-LL) and heart rate during deep breathing (HRDB).

Results

Improvement and prevention of progression of NIS-LL (ΔNIS-LL  2 points) with ALA vs. placebo after 4 years was predicted by higher age, lower BMI, male sex, normal blood pressure, history of cardiovascular disease (CVD), insulin treatment, longer duration of diabetes and neuropathy, and higher neuropathy stage. Participants treated with ALA who received ACE inhibitors showed a better outcome in HRDB after 4 years.

Conclusions

Better outcome in neuropathic impairments following 4-year treatment with α-lipoic acid was predicted by normal BMI and blood pressure and higher burden due to CVD, diabetes, and neuropathy, while improvement in cardiac autonomic function was predicted by ACE inhibitor treatment. Thus, optimal control of CVD risk factors could contribute to improved efficacy of α-lipoic acid in patients with higher disease burden.

Introduction

About one third of all patients with diabetes are affected by diabetic sensorimotor polyneuropathy (DSPN) which has a major impact on morbidity and mortality (Ziegler, Papanas, Vinik, & Shaw, 2014). Neuropathic sensory deficits such as reduced touch and vibration perception are independent predictors of mortality (Coppini, Bowtell, Weng, Young, & Sönksen, 2000), cardiac death or nonfatal myocardial infarction (Young et al., 2009), incident cardiovascular disease (CVD) events (Brownrigg et al., 2014), and lower-limb amputation (Rajamani et al., 2009). On the other hand, history of myocardial infarction and CVD and the underlying risk factors such as obesity, hypertension, and hyperlipidemia may predict the risk of developing DSPN (Forrest et al., 1997, Sands et al., 1997, Tesfaye et al., 2005, Wiggin et al., 2009, Ylitalo et al., 2011, Ziegler et al., 2008, Ziegler et al., 2009).

Effective causal treatment of DSPN remains challenging for the physician. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study demonstrated that intensive diabetes therapy in type 1 diabetic individual retards but not fully prevents the development of DSPN and cardiovascular autonomic neuropathy (CAN) (Martin et al., 2014, The Diabetes Control and Complications Trial Research Group, 1993). In contrast, there is no clear evidence that intensive diabetes therapy or a target-driven intensified intervention aimed at multiple risk cardiovascular factors favorably influence the development or progression of DSPN and CAN in type 2 diabetic subjects (Boussageon et al., 2011, Charles et al., 2011, Charles et al., 2013, Gaede et al., 2008, Sandbæk et al., 2014). In fact, self-reported history of neuropathy was a significant predictor for increased mortality in patients with type 2 diabetes allocated to a very intensive diabetes therapy aimed at HbA1c < 6.0% in the ACCORD trial (Calles-Escandón 2010). On the other hand, near-normoglycemia is difficult to achieve in a considerable number of individuals with diabetes. Thus, there is an unmet need for disease-modifying treatments considering the pathogenetic mechanisms contributing to DSPN. Since diabetic neuropathy is closely linked to CVD and both oxidative stress and vascular dysfunction play a paramount pathogenetic role (Nishikawa et al., 2000, Ziegler, Buchholz, et al., 2015), agents that reduce oxidative stress such as α-lipoic acid (ALA) and those ameliorating vascular dysfunction and promote vasodilatation such as ACE inhibitors have been evaluated in clinical trials showing improvement of DSPN and CAN (Malik et al., 1998, Papanas and Ziegler, 2014, Ruggenenti et al., 2011).

The efficacy and safety of ALA have been assessed in several controlled clinical trials and meta-analyses (Papanas & Ziegler, 2014). In the NATHAN 1 trial, we evaluated the efficacy and safety of α-lipoic acid over 4 years in patients with mild-to-moderate DSPN (Ziegler et al., 2011). The primary outcome measure was a composite score including the Neuropathy Impairment Score of the lower limbs and 7 nerve function tests (NIS-LL + 7 tests). Primary analysis showed no significant difference between the groups for the changes in NIS-LL + 7 tests from baseline to 4 years (p = 0.105). The lack of improvement in the composite score was predominantly due to the fact that nerve conduction deficits in the placebo-treated group did not progress. In contrast, improvement on ALA vs. placebo was noted for NIS (p = 0.028) and NIS-LL (p = 0.05). More patients showed a clinically meaningful response and fewer showed progression with ALA than with placebo for NIS (p = 0.013) and NIS-LL (p = 0.025), respectively. The changes in nerve conduction and quantitative sensory testing did not differ between both groups after 4 years (Ziegler et al., 2011).

Based on the epidemiological and clinical evidence, here we hypothesized that CVD and its underlying risk factors which are frequently encountered in type 2 diabetic patients and the concomitant pharmacotherapy could modify the effect of ALA on neuropathy outcomes. Thus, in the present post-hoc analysis of the NATHAN 1 study, we aimed to determine the baseline factors that may predict effect of ALA on neuropathic impairments and cardiac autonomic function focusing on CVD and its risk factors such as obesity and hypertension as well as concomitant medication.

Section snippets

Study population and methods

The NATHAN (Neurological Assessment of Thioctic Acid in Diabetic Neuropathy) 1 trial was a multicenter (36 centers in USA, Canada, and Europe), randomized, double-blind, placebo-controlled, two-arm, 1:1 allocation ratio, parallel-group clinical trial using film-coated tablets containing ALA 600 mg qd (Thioctacid® HR, MEDA Pharma GmbH & Co. KG, Bad Homburg, Germany) or matching placebo tablets in diabetic patients with mild-to-moderate polyneuropathy. Approvals were obtained from the local ethics

Results

The changes in NIS-LL from baseline to 4 years in the different baseline subcategories and treatment groups are shown in Table 2. The numerically highest (more than − 1 point) mean improvements in NIS-LL during ALA treatment were observed in the baseline subcategories with BMI < 30 kg/m2, type 1 diabetes, clinically relevant smoking (yes), and ACE inhibitor treatment (yes), while the highest (more than 1 point) incremental mean NIS-LL (progression) during placebo treatment was noted for the

Discussion

The results of this post-hoc analysis of the NATHAN 1 trial demonstrate that improvement and prevention of progression of neuropathic impairments after 4 years of treatment with ALA were predicted by normal values of modifiable cardiovascular risk factors such as BMI and blood pressure, but on the other hand also by a higher burden due to CVD, diabetes, and neuropathy, suggesting that optimal control of CVD risk factors could contribute to improved efficacy of ALA in diabetic polyneuropathy. In

Author contributions

DZ, PAL, RF, HT, and AIV contributed to the study design. DZ, PAL, RF, HT, and AIV participated in the acquisition and interpretation of the data. DZ contributed to data analysis. DZ wrote the manuscript, PAL, RF, HT, and AIV reviewed the manuscript. DZ is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements

The authors wish to thank Dr. Hans Christian Kuhl, Biometrics Department, MEDA Pharma GmbH & Co. KG, for statistical analyses, Dr. Alexander Strom for drawing the figures, and all investigators, subinvestigators, and volunteers participating in this trial. This work was sponsored by MEDA Pharma GmbH & Co. KG, Bad Homburg, Germany.

References (40)

  • R. Boussageon et al.

    Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials

    BMJ

    (2011)
  • J.R. Brownrigg et al.

    Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus

    Heart

    (2014)
  • J. Calles-Escandón et al.

    Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

    Diabetes Care

    (2010)
  • M. Charles et al.

    Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: The ADDITION-Denmark study

    Diabetes Care

    (2011)
  • M. Charles et al.

    Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study

    Diabetologia

    (2013)
  • D.V. Coppini et al.

    Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model

    Journal of Clinical Epidemiology

    (2000)
  • R.H. Dworkin et al.

    Assay sensitivity and study features in neuropathic pain trials: An ACTTION meta-analysis

    Neurology

    (2013)
  • P.J. Dyck et al.

    Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

    Neurology

    (1997)
  • P.J. Dyck et al.

    Challenges in design of multicenter trials: End points assessed longitudinally for change and monotonicity

    Diabetes Care

    (2007)
  • K.Y. Forrest et al.

    Hypertension as a risk factor for diabetic neuropathy: A prospective study

    Diabetes

    (1997)
  • Cited by (66)

    • Activation of renal CSE/H<inf>2</inf>S pathway by alpha-lipoic acid protects against histological and functional changes in the diabetic kidney

      2022, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Besides persistent hyperglycemia and ROS-induced oxidative stress, other related molecular mechanisms are being identified with novel pharmacological agents and strategies in an attempt to prevent or reverse DKD and other diabetic complications. We previously reported that supplementation of anti-diabetic therapy with alpha-lipoic acid (ALA), a sulfur-containing ROS-scavenging thiol compound produced from octanoic acid and cysteine (as a sulfur donor) by lipoic acid synthase in the mitochondria of kidney and other tissues [15,16], improves glycemic control and protects against development and progression of DKD [17] and other diabetic complications [18–20], with beneficial effect in patients on dialysis [21]. Besides its endogenous production, ALA can also be obtained from exogenous sources including dietary sources, and is reduced enzymatically to dihydrolipoic acid (DHLA) in the body after exogenous administration [22].

    • Evaluation of the analgesic effect of ɑ-lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials

      2022, Pharmacological Research
      Citation Excerpt :

      In the same way, the QST was only used by Ziegler (2011) [9], and no difference was observed between ALA patients and placebo. Ziegler 2011 [9] and 2016 [38] also evaluated the cold detection threshold, which did not differ between ALA treatment and placebo. Finally, in Reljanovic (2009) [33] the motor nerve distal latency (MNDL) did not differ between the ALA and placebo groups.

    View all citing articles on Scopus

    Conflict of interest: DZ received honoraria for speaking and consulting activities from MEDA Pharma. HT is employee of MEDA Pharma.

    ClinicalTrials.gov Identifier: NCT00977483

    View full text